IP Library Granted Patent US 8,835,386
Granted Patent B2
US 8,835,386 · App. 12/325,084 · Granted Sep 16, 2014

Activity of recombinant equine follicle stimulating hormone

Inventors: Mark Colgin (Castle Rock, CO); Kory Niswender (Weatherford, TX); Irving Boime (St. Louis, MO); Janet Roser (Davis, CA)
Assignees: Venaxis, Inc.; Washington University; The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,835,386
App. No.
12/325,084
Granted
Sep 16, 2014
Kind
B2
Abstract

The present invention provides methods of producing biologically active recombinant eFSH analogs and methods of increasing reproduction in mammals, particularly equine, using recombinant eFSH analogs. Also provided are methods of producing biologically active single chain recombinant eFSH. The recombinant eFSH analogs of the present invention increase superovulation, follicular development, embryo development, and reproductive efficiency in horses, cattle and other ungulates.

Claims (7)

1. A method of stimulating follicular development or superovulation in an ungulate comprising administering an effective amount of an equine follicle stimulating hormone (eFSH) analog to said ungulate, wherein said eFSH analog comprises a first polypeptide having at least 95% homology with SEQ ID NO 5, and a second polypeptide having at least 95% homology with SEQ ID NO 6, wherein said first and second polypeptides are covalently linked by an equine chorionic gonadotropin carboxy terminal peptide (CTP) having at least 90% homology with SEQ ID NO 7, wherein said effective amount is between approximately 200 μg and approximately 1.0 mg administered daily to said ungulate for approximately 4 to 9 days between day 6 to day 16 after ovulation.

2. The method of claim 1 wherein said ungulates are equine.

3. The method of claim 1 further comprising inseminating said ungulate between 2 to 8 days after administrating said eFSH analog.

4. The method of claim 1 wherein said eFSH analog has at least 95% homology with the full length sequence of SEQ ID NO 8.

5. The method of claim 1 wherein said effective amount is between approximately 500 μg and approximately 850 μg.

6. The method of claim 1 wherein a dose of the eFSH analog is administered daily to said ungulate for approximately 5 to 8 days in a single estrus cycle.

7. The method of claim 6 wherein a dose of the eFSH analog is administered twice daily to said ungulate for approximately 5 to 8 days in a single estrus cycle.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2014
From: COLGIN, MARK; ROSER, JANET
To: ASPENBIO PHARMA, INC.
Reel/Frame 033875/0001 →
CHANGE OF NAME Recorded Oct 2, 2014
From: ASPENBIO PHARMA, INC.
To: VENAXIS, INC
Reel/Frame 033887/0053 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2014
From: NISWENDER, KORY
To: ASPENBIO PHARMA, INC.
Reel/Frame 033758/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2014
From: COLGIN, MARK A.
To: VENAXIS, INC
Reel/Frame 032968/0797 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2014
From: BOIME, IRVING
To: WASHINGTON UNIVERSITY
Reel/Frame 032968/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2014
From: ROSER, JANET F.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 032968/0902 →
Continuity (2)
Provisional Application 60991297 · Nov 30, 2007
Related Publication 20100120677A1 · May 13, 2010